Abstract: Dialyzer systems can consolidate multiple technologies and functionalities of blood treatment systems in a significantly integrated fashion. For example, this disclosure describes dialyzer systems that include a magnetically driven and magnetically levitating pump rotor integrated into the dialyzer. Such a dialyzer can be used with treatment modules that include a magnetic field-generating pump drive unit. In some embodiments, the dialyzers include pressure sensor chambers with flexible membranes with which corresponding pressure transducers of the treatment modules can interface to detect arterial and/or venous pressures.

Abstract: A wood heating system comprises an electric power source, a first electrode assembly, a second electrode assembly, and a control system. The first electrode assembly is connected to the electric power source and is adapted to make electrical contact with a first end of a wood length to apply electric power to the wood length. The first electrode assembly comprises at least two electrode segments. The second electrode assembly is adapted to make electrical contact with a second end of the wood length. The control system is adapted to selectively connect/disconnect electric power flow between the electric power source and at least one electrode segment of the first electrode assembly.

Abstract: A wood heating system comprises an electric power source, a first electrode assembly, a second electrode assembly, and a control system. The first electrode assembly is connected to the electric power source and is adapted to make electrical contact with a first end of a wood length to apply electric power to the wood length. The first electrode assembly comprises at least two electrode segments. The second electrode assembly is adapted to make electrical contact with a second end of the wood length. The control system is adapted to selectively connect/disconnect electric power flow between the electric power source and at least one electrode segment of the first electrode assembly.

Abstract: A PMOS non-volatile memory array using SONOS transistors having program and erase threshold voltages for representing digital logic states of zero and one and selected to optimize read disturb characteristics. The threshold voltages are linearly convergent and separated by at least 0.5 volts for a charge retention time of at least 10 years, with the threshold voltages defining a window wherein a read voltage for selected memory transistors can be held flat and not intersect the threshold voltages. The lower threshold is selected to be at a zero charge state for one of the two logic levels of the memory.

Abstract: A PMOS non-volatile memory array using SONOS transistors having program and erase threshold voltages for representing digital logic states of zero and one and selected to optimize read disturb characteristics. The threshold voltages are linearly convergent and separated by at least 0.5 volts for a charge retention time of at least 10 years, with the threshold voltages defining a window wherein a read voltage for selected memory transistors can be held flat and not intersect the threshold voltages. The lower threshold is selected to be at a zero charge state for one of the two logic levels of the memory.

Abstract: A method of treating eczema in a human or other mammal in need thereof comprising administering systemically to said human or other mammal a tetracycline compound in an amount that is effective to treat eczema, but has substantially no antibacterial activity.

Abstract: The present invention relates to a method for decreasing elevated serum/plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.

Abstract: The present invention relates to a method for decreasing elevated serum/plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.